Fox Run Management’s Arcturus Therapeutics ARCT Stock Holding History

Fox Run Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$159K	Buy	+11,628	New	+$122K	0.02%	882

Other funds holding ARCT

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Empire Life Investments Toronto, Ontario, Canada $1.83B AUM 33.18% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Fox Run Management's ARCT Position: Q3 2026 in Review

Fox Run Management opened a new position in Arcturus Therapeutics (ARCT) in Q3 2026: 11,628 shares worth $159K. The stake represents 0.02% of the portfolio and ranks #882 among its holdings.

90 funds tracked by Wall St. Rank hold ARCT as of Q3 2026.

Fox Run Management held 11,628 shares of Arcturus Therapeutics worth $159K as of Q3 2026.
Arcturus Therapeutics was a new Fox Run Management position in Q3 2026.
Arcturus Therapeutics made up 0.02% of Fox Run Management's portfolio in Q3 2026, its #882 holding.
90 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2026.

Based on Fox Run Management's 13F filing for Q3 2026, filed 12 Nov 2026.